Cargando…
TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
We previously reported that SNPs near TSPAN5 were associated with plasma serotonin (5-HT) concentrations which were themselves associated with selective serotonin reuptake inhibitor treatment outcomes in patients with major depressive disorder (MDD). TSPAN5 SNPs were also associated with alcohol con...
Autores principales: | Ho, Ming-Fen, Zhang, Cheng, Zhang, Lingxin, Wei, Lixuan, Zhou, Ying, Moon, Irene, Geske, Jennifer R., Choi, Doo-Sup, Biernacka, Joanna, Frye, Mark, Wen, Zhexing, Karpyak, Victor M., Li, Hu, Weinshilboum, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858703/ https://www.ncbi.nlm.nih.gov/pubmed/32753686 http://dx.doi.org/10.1038/s41380-020-0855-9 |
Ejemplares similares
-
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
por: Ho, Ming‐Fen, et al.
Publicado: (2022) -
Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder
por: Ho, Ming-Fen, et al.
Publicado: (2022) -
PM307. Untargeted Global Metabolomics Reveals Metabolites Associated with Acamprosate Treatment Outcome
por: Ho, Ada, et al.
Publicado: (2016) -
Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects
por: Hinton, David J., et al.
Publicado: (2017) -
Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects
por: Nam, H W, et al.
Publicado: (2015)